Directors Receive Shares in Lieu of Fees
London and New York, 16 October 2009 - Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, today announces that, at a Board meeting held today, the Company has issued 302,861 ordinary shares, representing 0.23% of the enlarged issued share capital, to certain of its Board members, in lieu of their directors’ fees for the third quarter to September 2009, priced at 14.85p, being the average of the closing mid-market price for the five days leading up to the market close on 30 September 2009. Following this issue, the directors’ shareholdings in the Company are as follows:
|Director||Number of New Shares||Price||Total Shareholding||Percentage of voting rights|
|R. James Macaleer||57,548||14.85||22,501,692||17.01%|
In addition, Board members Richard Mansell-Jones and Anthony Henfrey have used part of their directors’ fees for the third quarter to 30 September 2009, to subscribe to the convertible promissory note offering for a total of £8,591.
|Director||New Promissory Note||Total Holding of Promissory Notes||Conversion Price||New Warrants||Total Warrants|
The Convertible Promissory Notes are convertible between 31 December 2008 to 31 December 2013 into fully paid Ordinary Shares of 1 pence each in the capital of the Company at a conversion price of 18 pence per Ordinary Share and pay interest of 7 per cent annually until conversion. In addition, for each Note issued, the Company also issued 1.11 warrants to each subscriber of the Notes, a ratio of one warrant for every five shares issuable upon conversion. Each warrant will entitle the holder to subscribe for one Ordinary Share at 20 pence per Ordinary Share.
Admission of the 302,861 new ordinary shares, ranking pari passu, is expected on 21 October 2009. Following this allotment the total issued share capital of the Company will increase to 132,258,897 ordinary shares.
For further information please contact
Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 (212) 210 6224
Tim Robertson/ Jamie Milton/ Matthew Law
+44 20 7930 0777
Charles Stanley (Nominated Adviser)
Mark Taylor/ Freddy Crossley/Jen Boorer
+44 20 7149 6000
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in ten Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
On the web: www.amphionplc.com